- $79.49m
- -$15.45m
- €0.06m
- 19
- 19
- 28
- 11
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.73 | ||
| Price to Tang. Book | 0.73 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1,182.64 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -43.45% | ||
| Return on Equity | -44.69% | ||
| Operating Margin | -71181.01% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | n/a | n/a | n/a | n/a | 0.06 | 4.47 | 7.13 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- June 6th, 2017
- Public Since
- November 16th, 2017
- No. of Shareholders
- 20
- No. of Employees
- 66
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 58,883,272
- Address
- Winzerlaer Str. 2, JENA, 07745
- Web
- https://www.inflarx.de/
- Phone
- +49 3641508180
- Auditors
- Ernst & Young Wirtschaftsprufungsgesellschaft
Upcoming Events for IFRX
Q2 2024 InflaRx NV Earnings Release
Similar to IFRX
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Inflarx NV share price?
As of Today at 19:11 UTC, shares in Inflarx NV are trading at $1.35. This share price information is delayed by 15 minutes.
How has the Inflarx NV share price performed this year?
Shares in Inflarx NV last closed at $1.35 and the price had moved by -71.28% over the past 365 days. In terms of relative price strength the Inflarx NV share price has underperformed the S&P500 Index by -76.1% over the past year.
What are the analyst and broker recommendations for Inflarx NV?
The overall consensus recommendation for Inflarx NV is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Inflarx NV dividend yield?
Inflarx NV does not currently pay a dividend.
Does Inflarx NV pay a dividend?
Inflarx NV does not currently pay a dividend.
When does Inflarx NV next pay dividends?
Inflarx NV does not currently pay a dividend.
How do I buy Inflarx NV shares?
To buy shares in Inflarx NV you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Inflarx NV?
As of the previous close price of $1.35, shares in Inflarx NV had a market capitalisation of $79.49m.
Where are Inflarx NV shares listed?
Here are the trading details for Inflarx NV:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: IFRX
What kind of share is Inflarx NV?
Based on an overall assessment of its quality, value and momentum Inflarx NV is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Inflarx NV share price forecast for 2024?
The analyst consensus target price for shares in Inflarx NV is $7.98. That is 491.28% above the last closing price of $1.35.
Analysts covering Inflarx NV currently have a consensus Earnings Per Share (EPS) forecast of -€0.92 for the next financial year.
What is the trend in the Inflarx NV share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Inflarx NV. Over the past six months, its share price has underperformed the S&P500 Index by -42.69%.
As of the last closing price of $1.35, shares in Inflarx NV were trading -41.43% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Inflarx NV PE Ratio?
The Inflarx NV PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.35.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Inflarx NV?
We do not have data on Inflarx NV's directors